AKOUOS Trademark

Trademark Overview

On Friday, November 20, 2020, a trademark application was filed for AKOUOS with the United States Patent and Trademark Office. The USPTO has given the AKOUOS trademark a serial number of 90332974. The federal status of this trademark filing is SU - REGISTRATION REVIEW COMPLETE as of Tuesday, October 29, 2024. This trademark is owned by Akouos, Inc.. The AKOUOS trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Scientific research consulting in the field of inner ear disorders and conditions and other causes of hearing loss; custom development of biochemical reagents and biological nanoparticles for therapeutic use featuring adeno-associated viral (AAV) vectors therein to provide platforms for specific expressions of biologics with therapeutic effects in gene therapy, all to restore, improve and preserve hearing; custom development of biochemical reagents and biological nanoparticles for therapeutic use featuring adeno-associated viral (AAV) vectors therein to provide platforms for specific expressions of biologics with therapeutic effects in gene therapy, all to treat inner ear disorders and conditions
akouos

General Information

Serial Number90332974
Word MarkAKOUOS
Filing DateFriday, November 20, 2020
Status819 - SU - REGISTRATION REVIEW COMPLETE
Status DateTuesday, October 29, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, June 15, 2021

Trademark Statements

Translation of Words in MarkThe wording "Akouos" has no meaning in a foreign language.
Goods and ServicesScientific research consulting in the field of inner ear disorders and conditions and other causes of hearing loss; custom development of biochemical reagents and biological nanoparticles for therapeutic use featuring adeno-associated viral (AAV) vectors therein to provide platforms for specific expressions of biologics with therapeutic effects in gene therapy, all to restore, improve and preserve hearing; custom development of biochemical reagents and biological nanoparticles for therapeutic use featuring adeno-associated viral (AAV) vectors therein to provide platforms for specific expressions of biologics with therapeutic effects in gene therapy, all to treat inner ear disorders and conditions

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateTuesday, January 26, 2021
Primary Code042
First Use Anywhere DateTuesday, July 16, 2024
First Use In Commerce DateTuesday, July 16, 2024

Trademark Owner History

Party NameAkouos, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressBoston, MA 02210
Party NameAkouos, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressBoston, MA 02210

Trademark Events

Event DateEvent Description
Friday, May 7, 2021TEAS VOLUNTARY AMENDMENT RECEIVED
Tuesday, November 24, 2020NEW APPLICATION ENTERED
Tuesday, January 26, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, May 4, 2021ASSIGNED TO EXAMINER
Tuesday, May 11, 2021PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
Tuesday, May 11, 2021EXAMINERS AMENDMENT -WRITTEN
Tuesday, May 11, 2021EXAMINERS AMENDMENT E-MAILED
Tuesday, May 11, 2021NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Tuesday, May 11, 2021EXAMINER'S AMENDMENT ENTERED
Tuesday, May 11, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, May 26, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, June 15, 2021PUBLISHED FOR OPPOSITION
Tuesday, June 15, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, August 10, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, February 8, 2022SOU TEAS EXTENSION RECEIVED
Tuesday, February 8, 2022SOU EXTENSION 1 FILED
Tuesday, February 8, 2022SOU EXTENSION 1 GRANTED
Thursday, February 10, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, August 9, 2022SOU TEAS EXTENSION RECEIVED
Tuesday, August 9, 2022SOU EXTENSION 2 FILED
Tuesday, August 9, 2022SOU EXTENSION 2 GRANTED
Thursday, August 11, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, February 7, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, February 7, 2023SOU EXTENSION 3 FILED
Tuesday, February 7, 2023SOU EXTENSION 3 GRANTED
Thursday, February 9, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, August 2, 2023SOU TEAS EXTENSION RECEIVED
Wednesday, August 2, 2023SOU EXTENSION 4 FILED
Wednesday, August 2, 2023SOU EXTENSION 4 GRANTED
Thursday, August 3, 2023TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, August 3, 2023ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, August 3, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, August 4, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, September 13, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Wednesday, September 13, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, September 13, 2023TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, September 13, 2023ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, September 13, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, January 16, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, January 16, 2024SOU EXTENSION 5 FILED
Wednesday, January 31, 2024CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, February 21, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, February 20, 2024SOU EXTENSION 5 GRANTED
Tuesday, July 23, 2024USE AMENDMENT FILED
Tuesday, July 23, 2024TEAS STATEMENT OF USE RECEIVED
Saturday, August 3, 2024STATEMENT OF USE PROCESSING COMPLETE
Tuesday, October 29, 2024NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Tuesday, October 29, 2024ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED

Related Keywords

akouos therapeutic therein provide vectors viral adeno associated platforms specific gene